Comparison of EGF with VEGF Non-Viral Gene Therapy for Cutaneous Wound Healing of Streptozotocin Diabetic Mice

• DOI: 10.4093/dmj.2011.35.3.226
• Publication Date: 2011-07-13T07:20:45Z
• Authors: Junghae Ko; Haejung Jun; Hyesook Chung; Changshin Yoon; Taekyoon Kim; Minjeong Kwon; Soonhee Lee; Soojin Jung; Mikyung Kim; Jeong Hyun Park
• Keywords: 0303 health sciences; 03 medical and health sciences; Gene therapy; Skin wound; Non-viral; Epidermal growth factor; Original Article; Vascular endothelial growth factor; RC648-665; Diseases of the endocrine glands. Clinical endocrinology; 3. Good health

To accelerate the healing of diabetic wounds, various kinds growth factors have been employed. It is short half-life administered in hostile wound beds that limited wide-spread clinical usage. overcome this limitation, factor gene therapy could be an attractive alternative rather than direct application onto beds. We two DNAs, epidermal (EGF) and vascular endothelial (VEGF) into a cutaneous on mice. compared different characteristics wounds.Streptozotocin was injected intraperitoneally to induce diabetes C57BL/6J The ultrasound micro-bubble destruction method with SonoVue as bubbling agent used for non-viral delivery EGF(828) VEGF(165) DNAs. Each modified increasing efficacy FRM-EGF(828) or minicircle VEGF(165). degree neoangiogenesis assessed using qualitative laser Doppler flowmetry. size histological findings skin wounds each group.In both groups, accelerated closure observed mice receiving non treated control Blood flow detected by doppler flowmetry better VEGF group EGF group. Wound rates were more group, but not statistically significant.Both administrations improve speed quality healing. However, detailed different.